我国有近七成的初诊肝癌患者为不可手术切除的中晚期肝癌，整体的5年生存率较低、预后较差。近年来，不断发展的介入治疗、靶向治疗为中晚期肝癌患者提供了转化治疗的手段，也进一步拓展了肝癌转化治疗的内涵。
Video Player is loading.
Current Time 0:00
Duration 0:00
Remaining Time -0:00
This is a modal window.
The media could not be loaded, either because the server or network failed or because the format is not supported.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
赵明教授：提高我国肝癌患者的5年生存率，首先是要强调“早诊早治”。我们知道日本的肝癌5年生存率已达到60%，远远高于我国的14%，其最主要的原因是他们的肝癌早筛水平很高。实际上，日本有的肝癌治疗技术，我们也已经有了。但我国的肝癌筛查还不够，而且存在较大的地区差异。由于早期肝癌的5年生存率可以达到70%以上，小肝癌甚至可达90%以上，所以提高早诊早治水平，是提高我国肝癌整体生存率的关键所在。
再者，我们要强调提高肝癌的规范化诊疗水平。随着肝癌诊疗技术的进步，我们现在有了介入、消融、手术等局部治疗，还有化疗、靶向、免疫等众多系统治疗，不同分期的肝癌患者，需要不同学科的参与。在多学科协作（MDT）模式下，可以为患者提供更加个体化的最佳治疗决策。
最后，我们要继续不断创新。其实不同治疗手段都有其优势和局限性，外科、介入医生也要掌握药物治疗的相关机制，才能更好地将局部治疗与系统治疗联合。比如今年Kudo教授发表的一项如何减少肝癌术后复发的研究，对于病理检测T细胞富集的肿瘤，术后给予免疫治疗可以减少复发，对于富含MDSC等免疫抑制细胞的肿瘤，术后免疫治疗的效果很差。
希望通过大家的努力，能够进一步推动肝癌诊疗技术的发展，让更多肝癌患者获得及时、规范的治疗，从而改善患者预后，早日实现“健康中国2030”的伟大蓝图。
仑伐替尼携手介入、免疫共铸抗癌“利剑“，重磅研究亮相ESMO 2021
国内前沿研究
1.938P - 一项前瞻性、II期试验用以评估KN046联合仑伐替尼（LEN）在治疗晚期不可切除或转移性肝细胞癌中的疗效及安全性
KN046 (an anti-PD-L1/CTLA-4 Bispecific Antibody) in combination with Lenvatinib in the treatment for advanced unresectable or metastatic hepatocellular carcinoma (HCC): preliminary efficacy and safety results of a prospective phase II trial
BaoCai Xing
Beijing， China
2.948P - 基于MRI提取的肿瘤放射数据，用以预测LEN联合 PD-1 单抗在不可切除肝细胞癌（uHCC）治疗中的疗效
Predicting the efficacy of lenvatinib plus anti-PD-1 antibodies in unresectable hepatocellular carcinoma (uHCC) using radiomics features of tumors extracted from baseline MRI
Huichuan Sun
Shanghai， China
3.945P - LEN联合TACE，用于术后具有高复发风险的肝细胞癌患者辅助治疗：多中心前瞻性队列研究的最新结果
Adjuvant Lenvatinib in combination with TACE for hepatocellular carcinoma patients with high risk of postoperative relapse (LANCE): updated results from a multi-center perspective cohort study
Jinhong Chen
Shanghai， China
国外前沿研究
1.937P - LEN联合HAIC治疗晚期肝细胞癌的多中心II期研究
Multicenter Phase II trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: LEOPARD
Masafumi Ikeda
Kashiwa， Chiba， Japan
2.506TiP - 帕博利珠单抗联合LEN对比SoC后线治疗转移性结直肠癌的III期研究
Pembrolizumab Plus Lenvatinib Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer (mCRC): Phase 3 LEAP-017 Study
Takayuki Yoshino
Kashiwa， Chiba， Japan
3.726MO - LEN联合帕博利珠单抗相比医生选择的治疗，基于组织学和一线治疗在晚期子宫内膜癌患者中的疗效
Outcomes by Histology and Prior Therapy with Lenvatinib Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients with Advanced Endometrial Cancer (Study 309/KEYNOTE-775)
Nicoletta Colombo
Milan， Italy
4.717TiP - MK-1308A+LEN与帕博利珠单抗+Belzutifan+LEN或与帕博利珠单抗+LEN作为晚期肾透明细胞癌一线治疗的III期试验
Randomized， Open-Label， 3-Arm Phase 3 Study Comparing MK-1308A + Lenvatinib and Pembrolizumab (Pembro) + Belzutifan + Lenvatinib versus Pembro + Lenvatinib as First line (1L) Treatment for Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Brian I. Rini
Cleveland， OH， United States of America
5.8P - 同源小鼠模型中与LEN联合 PD-1 单抗抗肿瘤活性相关的肿瘤特征
The characterization of tumors associated with the antitumor activity of lenvatinib plus anti-PD-1 antibody combination therapy in a mouse syngeneic model panel
Yoichi Ozawa
Tsukuba， Japan
6.1555TiP - 帕博利珠单抗联合LEN后线治疗经典卡波西肉瘤的研究
A Phase II single-arm study of PembrolizUmab plus Lenvatinib in previously treated classic Kaposi SARcoma (CKS): the PULSAR trial.
Alice Indini
Milan， Italy
7.640TiP - 帕博利珠单抗联合LEN治疗转移性去势抵抗性前列腺癌（mCRPC）或治疗神经内分泌性mCRPC患者的1b/II期研究
Phase 1b/2 Trial of Pembrolizumab (pembro) + Lenvatinib Combination Therapy in Patients (pts) With Adenocarcinoma Metastatic Castration-Resistant Prostate Cancer (mCRPC) or Treatment-Emergent Neuroendocrine mCRPC (t-NE): KEYNOTE-365 Cohorts E and
Gero Kramer
Vienna， Austria
8.796P - LEN联合帕博利珠单抗治疗晚期子宫内膜癌 (EC) 的生物标志物与临床结果之间的关联
Association Between Biomarkers and Clinical Outcomes of Lenvatinib (L) + Pembrolizumab (P) in Advanced Endometrial Cancer (EC): Results From KEYNOTE-146/Study 111
Vicky Makker
New York City， United States of America
9.571P - LEN在晚期放射性碘难治性分化型甲状腺癌 (rDTC) 患者中的疗效和耐药性的真实单中心回顾性研究
Real-life monocentric， retrospective study on efficacy and tolerability of Lenvatinib (Len) in patients (pts) with advanced radioactive iodine–refractory differentiated thyroid cancer (rDTC).
Stefania Zovato
Padova， Italy
10.1746P - 一项针对接受不同起始剂量LEN治疗的放射性碘难治性分化型甲状腺癌患者的II期研究---健康相关生活质量（HRQoL）分析
Health-related quality-of-life (HRQoL) analyses from Study 211—a phase 2 study in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) treated with 2 starting doses of lenvatinib (LEN)
Matthew H. Taylor
Portland， United States of America
11.660P - 晚期肾细胞癌 (aRCC) 的 III 期 CLEAR 试验：亚组结果和毒性更新
Phase 3 CLEAR Trial in Advanced Renal Cell Carcinoma (aRCC): Outcomes in Subgroups and Toxicity Update
Toni K. Choueiri
Boston， United States of America
12.667P - 免疫抑制剂联合靶向疗法治疗转移性肾细胞癌的成本效益
Cost Effectiveness of Immune Checkpoint Inhibitors in Combination with Targeted Therapies in Metastatic Renal Cell Carcinoma
Neil Mason
Tampa， United States of America
13.677P - 免疫疗法与舒尼替尼作为一线治疗晚期高危肾细胞癌患者的随机临床试验的荟萃分析
Immunotherapy vs sunitinib as first-line treatment for advanced renal cell carcinoma in favourable risk patients. A meta-analysis of randomized clinical trials
Ray Manneh Kopp
Valledupar， Atlantico， Colombia
京公网安备 11010502033352号